DOCSLIB.ORG

Enzyme Inhibitors Enzymes Are Biological Catalysts That Drive Various Reactions Within a Cell

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enzyme Inhibitors Enzymes Are Biological Catalysts That Drive Various Reactions Within a Cell Tech Help: Email: [email protected] | Toll Free: 800.891.9699 (US Only) | Enzyme Inhibitors Enzymes are biological catalysts that drive various reactions within a cell. They are required for nearly every function of a living cell/organism from digestion of food to the synthesis of DNA. Enzymes are usually very specific as to which reactions they catalyze and the substrates that are involved. Enzyme activity can be modulated by different classes of molecules. Enzyme Inhibitors are molecules that bind to the enzyme and decrease or completely stop their function. Since blocking the activity of an enzyme can have profound effects on the downstream cellular events sometimes with pathological or disease consequences, enzyme inhibition is a crucial component of new drug design. The discovery of new and potent enzyme inhibitors and developing better classes of inhibitors constitutes a dynamic branch of biochemical and pharmacological research in the area of Diabetes, Cancer, HIV and many more. BioVision offers a comprehensive collection of more than 800 enzyme inhibitors covering all the core biological/pharmacological research areas. ACAT (Acyl-CoA cholesteryl Acyl Transferase) Inhibitors Product Name Cat. No. Size CAS. No. Product Name Cat. No. Size CAS. No. Arecoline hydrobromide B1824 100 mg, 500 mg 300-08-3 Endostatin, human recombinant 4759 20 μg, 100 μg, 1 mg N/A Avasimibe 9506 5 mg, 25 mg 166518-60-1 Endostatin, human recombinant 4799 100 μg, 1 mg N/A Naringenin 1772 250 mg, 1 g 480-41-1 Fumagillin 2368 1 mg, 5 mg 23110-15-8 Pellitorine 2053 1 mg, 5 mg 18836-52-7 Isoxanthohumol 2529 5 mg, 25 mg 70872-29-6 Penicillide B1245 250 µg, 1 mg 55303-92-9 2-Methoxyestradiol 2166 5 mg, 25 mg 362-07-2 Pyripyropene A B1910 500 µg, 1 mg 147444-03-9 SKLB610 2610 5 mg, 25 mg 1125780-41-7 Terpendole C 2214 250 µg, 1 mg 156967-65-6 Thiabendazole 2161 1 g 148-79-8 TMP-153 B1181 10 mg, 50 mg 128831-46-9 Tranilast 1876 10 mg, 50 mg 53902-12-8 ACC (Acetyl-CoA Carboxylase) Inhibitors Angiotensin Receptor Antagonists Product Name Cat. No. Size CAS. No. Product Name Cat. No. Size CAS. No. ACC2 Inhibitor 1717 1 mg, 5 mg N/A BIBS39 B1071 5 mg, 25 mg 133085-33-3 CP-640186 9422 5 mg, 25 mg 591778-68-6 EXP-3174 9672 5 mg, 25 mg 124750-92-1 CP-640186 hydrochloride B1254 5 mg, 25 mg 591778-70-0 Losartan potassium 2750 50 mg, 250 mg 124750-99-8 Valsartan 2004 25 mg, 100 mg, 500 mg 137862-53-4 ACE (Angiotensin-Converting Enzyme) Inhibitors Product Name Cat. No. Size CAS. No. Arginase Inhibitors ACE2 Inhibitor, DX600 9687 100 µg, 500 µg, 1 mg N/A Product Name Cat. No. Size CAS. No. Captopril B1187 1 g, 5 g 62571-86-2 BEC 2359 1 mg, 5 mg 63107-40-4 Adenylase Cyclase Inhibitors Aromatase Inhibitors Product Name Cat. No. Size CAS. No. Product Name Cat. No. Size CAS. No. 2',5'-Dideoxyadenosine 2770 5 mg, 25 mg 6698-26-6 Exemestane 9473 5 mg, 25 mg 107868-30-4 KH7 2350 5 mg, 25 mg 330676-02-3 ATPase Inhibitors PACAP (human, chicken, mouse, ovine, B1562 100 μg, 500 μg 143748-18-9 porcine, rat) (6-38) Product Name Cat. No. Size CAS. No. SQ 22536 2019 5 mg, 25 mg 17318-31-9 Bafilomycin A1 1829 50 µg, 250 µg 88899-55-2 (-)-Blebbistatin 2406 1 mg, 5 mg 856925-71-8 AKR (Aldo-Keto Reductase) Inhibitors (+)-Blebbistatin 2407 1 mg, 5 mg 1177356-70-5 Product Name Cat. No. Size CAS. No. (±)-Blebbistatin 2405 5 mg, 25 mg 674289-55-5 AKR1C3 Inhibitor I 2403 5 mg, 25 mg N/A Bufalin 2509 10 mg, 50 mg 465-21-4 AKR1C3 Inhibitor II 2404 5 mg, 25 mg N/A Autophagy Inhibitors AKR1C3 Inhibitor III 2424 5 mg, 25 mg N/A Product Name Cat. No. Size CAS. No. Androgen Receptor Antagonists ATM Kinase Inhibitor, KU-55933 1685 5 mg 587871-26-9 Product Name Cat. No. Size CAS. No. Bafilomycin A1 1829 50 µg, 250 µg 88899-55-2 ARN-509 9535 5 mg, 25 mg 956104-40-8 Chloroquine Diphosphate 1825 100 mg, 500 mg 50-63-5 MDV-3100 9479 10 mg, 50 mg 915087-33-1 EZSolution™ Gö 6976 1785 500 µg 136194-77-9 ODM-201 9668 5 mg, 25 mg 1297538-32-9 Gö 6976 1711 500 µg 136194-77-9 Angiogenesis Inhibitors 3-Methyladenine 2249 25 mg, 100 mg 5142-23-4 Spautin-1 2037 5 mg, 25 mg 1262888-28-7 Product Name Cat. No. Size CAS. No. Angiostatin Human 4919 100 μg, 500 μg N/A Bcl-2 (B-cell lymphoma 2) Inhibitors Angiostatin K1-3, human recombinant 4920 20 μg, 100 μg, 1 mg N/A Product Name Cat. No. Size CAS. No. BIBF1120 2167 5 mg, 25 mg 928326-83-4 A-1155463 B1821 5 mg, 25 mg 1235034-55-5 Borrelidin 2367 250 µg, 1 mg 7184-60-3 A-1210477 B1826 5 mg, 25 mg 1668553-26-1 Castanospermine 2293 10 mg, 50 mg 79831-76-8 A-1331852 B1948 5 mg, 25 mg 1430844-80-6 Ordering: Email: [email protected] | Tel:408.493.1800 | Web: www.biovision.com 2 Product Name Cat. No. Size CAS. No. Product Name Cat. No. Size CAS. No. ABT-263 2467 5 mg, 25 mg 923564-51-6 110044-82-1 DiscoveryPak™ Calpain Inhibitors Set 136632-32-1 ABT-737 2463 5 mg, 25 mg 852808-04-9 (Containing Cat. No. 1834, 1835, 1506, S228 1 Set 133410-84-1 AT-101 2380 5 mg, 25 mg 90141-22-3 2195, 1906) 88191-84-8 BCl-2 Inhibitor GX15-070 2040 5 mg 803712-67-6 179528-45-1 MDL 28170 2195 10 mg, 50 mg 88191-84-8 BCl-2 Inhibitor, ABT-199 2253 1 mg, 5 mg 1257044-40-8 1257044-40-8 PD 150,606 1906 5 mg, 25 mg 179528-45-1 DiscoveryPak™ Bcl2 Inhibitors Set 923564-51-6 (Containing Cat. No. 2253, 2467, 2463, S229 1 Set 852808-04-9 Caspase & Granzyme B Inhibitors 2380, 2040) 90141-22-3 Product Name Cat. No. Size CAS. No. 803712-67-6 Ac-DEVD-CHO B1951 1 mg, 5 mg 169332-60-9 BDA366 B1827 5 mg, 25 mg 1909226-00-1 Apoptosis inhibitor 2783 5 mg, 25 mg 54135-60-3 BH3I-1 B1277 5 mg, 25 mg 300817-68-9 AZ10417808 2786 1 mg, 5 mg 331645-84-2 CC-122 B1650 5 mg, 25 mg 1015474-32-4 Biotin-DEVD-FMK 1124 20 µl (10 mM) N/A CID-5721353 B1275 5 mg, 25 mg 301356-95-6 Biotin-IETD-FMK 1121 20 µl (10 mM) N/A HA14-1 B1832 5 mg, 25 mg 65673-63-4 Biotin-VAD-FMK 1123 20 µl (10 mM) 1135688-15-1 Pyridoclax B1817 1 mg, 5 mg 1651890-44-6 Biotin-VDVAD-FMK 1032 20 µl (10 mM) N/A S63845 B1819 250 μg, 1 mg 1799633-27-4 Boc-D-FMK 1160 1 mg, 5 mg 187389-53-3 TW-37 2789 5 mg, 25 mg 877877-35-5 Caspase Family Inhibitor Set K107 5 x 25 µl N/A WEHI-539 B1818 5 mg, 25 mg 1431866-33-9 Caspase Family Inhibitor Set II K108 7 x 25 µl N/A BMP (Bone Morphogenetic Protein) Inhibitors Caspase Family Inhibitor Set III K210 8 x 25 µl N/A Product Name Cat. No. Size CAS. No. Caspase Family Inhibitor Set IV K220 12 x 25 µl N/A DMH-1 9542 5 mg, 25 mg 1206711-16-1 Caspase Inhibitor Boc-D-FMK 1120 20 µl (10 mM) 187389-53-3 EZSolution™ LDN193189 2092 5 mg 1062368-24-4 Caspase-1 Inhibitor Z-YVAD-FMK 1012 20 µl (10 mM), 100 µl (2 mM) N/A LDN193189 1995 5 mg, 25 mg 1062368-24-4 Caspase-10 Inhibitor AEVD-FMK 1112 20 µl (10 mM), 100 µl (2 mM) 1135688-47-9 Caspase-12 Inhibitor Z-ATAD-FMK 1079 20 µl (10 mM), 100 µl (2 mM) N/A Bone Resorption Inhibitors Caspase-13 Inhibitor LEED-FMK 1115 20 µl (10 mM), 100 µl (2 mM) N/A Product Name Cat. No. Size CAS. No. Caspase-2 Inhibitor Z-VDVAD-FMK 1073 20 µl (10 mM), 100 µl (2 mM) N/A Alendronate sodium 2168 50 mg, 250 mg 121268-17-5 Caspase-3 Inhibitor Q-DEVD-Oph 1175 1 mg, 3 mg, 5 mg N/A Pamidronate disodium 1884 50 mg, 250 mg 57248-88-1 Caspase-3 Inhibitor Z-DEVD-FMK 1009 20 µl (10 mM), 100 µl (2 mM) 210344-95-9 Zoledronic acid hydrate 2653 10 mg, 50 mg 165800-06-6 Caspase-3 inhibitor, Z-DQMD-FMK 2782 1 mg, 5 mg N/A Bromodomain Inhibitors Caspase-3/7 Inhibitor 2780 1 mg, 5 mg 220509-74-0 Caspase-4 Inhibitor Z-LEVD-FMK 1108 20 µl (10 mM), 100 µl (2 mM) N/A Product Name Cat. No. Size CAS. No. Caspase-5 Inhibitor Z-WEHD-FMK 1100 20 µl (10 mM), 100 µl (2 mM) N/A BAZ2-ICR B1865 5 mg, 25 mg 1665195-94-7 Caspase-6 Inhibitor Z-VEID-FMK 1011 20 µl (10 mM), 100 µl (2 mM) N/A BI-7273 B1879 5 mg, 25 mg 1883429-21-7 Caspase-8 Inhibitor Z-IETD-FMK 1064 20 µl (10 mM), 100 µl (2 mM) N/A BI-9564 B1880 5 mg, 25 mg 1883429-22-8 Caspase-8 Inhibitor, Q-IETD-Oph 1176 1 mg, 3 mg, 5 mg N/A Bromodomain Inhibitor, (+)-JQ1 2070 1 mg, 5 mg 1268524-70-4 Caspase-9 Inhibitor Z-LEHD-FMK 1074 20 µl (10 mM), 100 µl (2 mM) N/A Bromosporine 2652 1 mg, 5 mg 1619994-69-2 Caspase-9 Inhibitor, Q-LEHD-Oph 1177 1 mg, 3 mg, 5 mg N/A CPI-0610 B1201 5 mg, 25 mg 1380087-89-7 Caspase-Family Inhibitor Z-VAD-FMK 1010 20 µl (10 mM), 100 µl (2 mM) 187389-52-2 CPI-203 9404 1 mg, 5 mg 1446144-04-2 EMAP-II Inhibitor Z-ASTD-FMK 1127 20 µl (10 mM) N/A GSK-2801 9553 5 mg, 25 mg 1619994-68-1 FITC-DEVD-FMK 9499 100 Assays N/A I-BET151 2220 1 mg, 5 mg 1300031-49-5 FITC-IETD-FMK 9533 100 Assays N/A I-BET726 B1569 5 mg, 25 mg 1300031-52-0 FITC-LEHD-FMK 9534 100 Assays N/A I-BET762 2628 1 mg, 5 mg 1260907-17-2 FITC-VAD-FMK 9497 100 Assays N/A I-CBP112 9405 1 mg, 5 mg N/A FITC-VDVAD-FMK 9498 100 Assays N/A EZSolution™ (+)-JQ1 2091 1 mg 1268524-70-4 FMK Negative Control 1122 20 µl (10 mM), 100 µl (2 mM) 197855-65-5 (-)-JQ1 2384 1 mg 1268524-71-5 Granzyme B Inhibitor Ac-IEPD-CHO 1119 1 mg N/A Mivebresib B1564 5 mg, 25 mg 1445993-26-9 Granzyme B Inhibitor Z-AAD-CH2Cl 1128 20 µl (10 mM) N/A MS436 2680 5 mg, 25 mg 1395084-25-9 Ivachtin 2788 1 mg, 5 mg 745046-84-8 OF-1 9592 5 mg, 25 mg 919973-83-4 Pan-caspase inhibitor, Q-VD(OMe)-Oph 2787 1 mg, 5 mg N/A OTX015 2651 1 mg, 5 mg 202590-98-5 EZSolution™ Q-DEVD-Oph 1178 1 mg N/A PFI-1 2203 1 mg, 5 mg 1403764-72-6 EZSolution™ Q-VD-Oph 1173 1 mg 1135695-98-5 PFI-3 2895 5 mg, 25 mg 1819363-80-8 Q-VD-OPh 1170 1 mg, 3 mg, 5 mg 1135695-98-5 RVX-208 9408 1 mg, 5 mg 1044870-39-4 EZSolution™ Q-VD-OPh, Negative Control 1174 1 mg N/A SGC-CBP30 9554 5 mg, 25 mg 1613695-14-9 QVD-OPh Negative Control 1171 1 mg, 3 mg, 5 mg N/A Calpain Inhibitors VX-765 2781 5 mg, 25 mg 273404-37-8 Product Name Cat.
Load more

Recommended publications
  • Vandetanib-Eluting Beads for the Treatment of Liver Tumours
    VANDETANIB-ELUTING BEADS FOR THE TREATMENT OF LIVER TUMOURS ALICE HAGAN A thesis submitted in partial fulfilment of the requirements for the University of Brighton for the degree of Doctor of Philosophy June 2018 ABSTRACT Drug-eluting bead trans-arterial chemo-embolisation (DEB-TACE) is a minimally invasive interventional treatment for intermediate stage hepatocellular carcinoma (HCC). Drug loaded microspheres, such as DC Bead™ (Biocompatibles UK Ltd) are selectively delivered via catheterisation of the hepatic artery into tumour vasculature. The purpose of DEB-TACE is to physically embolise tumour-feeding vessels, starving the tumour of oxygen and nutrients, whilst releasing drug in a controlled manner. Due to the reduced systemic drug exposure, toxicity is greatly reduced. Embolisation-induced ischaemia is intended to cause tumour necrosis, however surviving hypoxic cells are known to activate hypoxia inducible factor (HIF-1) which leads to the upregulation of several pro-survival and pro-angiogenic pathways. This can lead to tumour revascularisation, recurrence and poor treatment outcomes, providing a rationale for combining anti-angiogenic agents with TACE treatment. Local delivery of these agents via DEBs could provide sustained targeted therapy in combination with embolisation, reducing systemic exposure and therefore toxicity associated with these drugs. This thesis describes for the first time the loading of the DEB DC Bead and the radiopaque DC Bead LUMI™ with the tyrosine kinase inhibitor vandetanib. Vandetanib selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor (EGFR), two signalling receptors involved in angiogenesis and HCC pathogenesis. Physicochemical properties of vandetanib loaded beads such as maximum loading capacity, effect on size, radiopacity and drug distribution were evaluated using various analytical techniques.
    [Show full text]
  • Tyrosine Kinase Inhibitors and Modifications of Thyroid Function Tests
    European Journal of Endocrinology (2009) 160 331–336 ISSN 0804-4643 REVIEW Tyrosine kinase inhibitors and modifications of thyroid function tests: a review Fre´de´ric Illouz1,2, Sandrine Laboureau-Soares1,Se´verine Dubois1, Vincent Rohmer1,2,3,4 and Patrice Rodien1,2,3,4 1CHU d’Angers, De´partement d’Endocrinologie Diabe´tologie Nutrition, Angers Cedex 09 F-49933, France, 2Centre de Re´fe´rence des Pathologies de la Re´ceptivite´ Hormonale, CHU d’Angers, Angers Cedex 09 F-49933, France, 3INSERM, U694, Angers Cedex 09 F-49933, France and 4Universite´ d’Angers, Angers Cedex 09 F-49933, France (Correspondence should be addressed to F Illouz; Email: [email protected]) Abstract Tyrosine kinase inhibitors (TKI) belong to new molecular multi-targeted therapies that are approved for the treatment of haematological and solid tumours. They interact with a large variety of protein tyrosine kinases involved in oncogenesis. In 2005, the first case of hypothyroidism was described and since then, some data have been published and have confirmed that TKI can affect the thyroid function tests (TFT). This review analyses the present clinical and fundamental findings about the effects of TKI on the thyroid function. Various hypotheses have been proposed to explain the effect of TKI on the thyroid function but those are mainly based on clinical observations. Moreover, it appears that TKI could alter the thyroid hormone regulation by mechanisms that are specific to each molecule. The present propositions for the management of TKI-induced hypothyroidism suggest that we assess the TFT of the patients regularly before and during the treatment by TKI.
    [Show full text]
  • A Human Multi-Lineage Hepatic Organoid Model for Liver Fibrosis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.01.278473; this version posted September 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. A Human Multi-Lineage Hepatic Organoid Model for Liver Fibrosis Yuan Guan1, Annika Enejder2, Meiyue Wang1, Zhuoqing Fang1, Lu Cui3, Shih-Yu Chen4, Jingxiao Wang1, Yalun Tan1, Manhong Wu1, Xinyu Chen1, Patrik K. Johansson2, Issra Osman1, Koshi Kunimoto3, Pierre Russo5, Sarah C. Heilshorn2 and Gary Peltz1* 1Department of Anesthesia, Stanford University School of Medicine, Stanford CA, 94305; 2Department of Materials Science and Engineering, Stanford University, Stanford CA, 94305; 3Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine (ISCBRM), Stanford University School of Medicine, Stanford, 94305, CA, USA; 4Shih-Yu Chen, Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan; 5Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA 19104 The authors have declared that no conflict of interest exists. *Address Correspondence to: [email protected] 300 Pasteur Dr. Room L232 Stanford, CA 94305. bioRxiv preprint doi: https://doi.org/10.1101/2020.09.01.278473; this version posted September 2, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Despite its devastating consequences, liver fibrosis has no treatments. Genome engineering and a hepatic organoid system was used to produce the first in vitro model for human liver fibrosis. Hepatic organoids engineered to express the most common causative mutation for Autosomal Recessive Polycystic Kidney Disease (ARPKD) developed the key features of ARPKD liver pathology (abnormal bile ducts and hepatic fibrosis) in only 21 days.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,375.433 B2 Dilly Et Al
    US009375433B2 (12) United States Patent (10) Patent No.: US 9,375.433 B2 Dilly et al. (45) Date of Patent: *Jun. 28, 2016 (54) MODULATORS OF ANDROGENSYNTHESIS (52) U.S. Cl. CPC ............. A6 IK3I/519 (2013.01); A61 K3I/201 (71) Applicant: Tangent Reprofiling Limited, London (2013.01); A61 K3I/202 (2013.01); A61 K (GB) 31/454 (2013.01); A61K 45/06 (2013.01) (72) Inventors: Suzanne Dilly, Oxfordshire (GB); (58) Field of Classification Search Gregory Stoloff, London (GB); Paul USPC .................................. 514/258,378,379, 560 Taylor, London (GB) See application file for complete search history. (73) Assignee: Tangent Reprofiling Limited, London (56) References Cited (GB) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 5,364,866 A * 1 1/1994 Strupczewski.......... CO7C 45/45 patent is extended or adjusted under 35 514,254.04 U.S.C. 154(b) by 0 days. 5,494.908 A * 2/1996 O’Malley ............. CO7D 261/20 514,228.2 This patent is Subject to a terminal dis 5,776,963 A * 7/1998 Strupczewski.......... CO7C 45/45 claimer. 514,217 6,977.271 B1* 12/2005 Ip ........................... A61K 31, 20 (21) Appl. No.: 14/708,052 514,560 OTHER PUBLICATIONS (22) Filed: May 8, 2015 Calabresi and Chabner (Goodman & Gilman's The Pharmacological (65) Prior Publication Data Basis of Therapeutics, 10th ed., 2001).* US 2015/O238491 A1 Aug. 27, 2015 (Cecil's Textbook of Medicine pp. 1060-1074 published 2000).* Stedman's Medical Dictionary (21st Edition, Published 2000).* Okamoto et al (Journal of Pain and Symptom Management vol.
    [Show full text]
  • Adaptive Stress Signaling in Targeted Cancer Therapy Resistance
    Oncogene (2015) 34, 5599–5606 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc REVIEW Adaptive stress signaling in targeted cancer therapy resistance E Pazarentzos1,2 and TG Bivona1,2 The identification of specific genetic alterations that drive the initiation and progression of cancer and the development of targeted drugs that act against these driver alterations has revolutionized the treatment of many human cancers. Although substantial progress has been achieved with the use of such targeted cancer therapies, resistance remains a major challenge that limits the overall clinical impact. Hence, despite progress, new strategies are needed to enhance response and eliminate resistance to targeted cancer therapies in order to achieve durable or curative responses in patients. To date, efforts to characterize mechanisms of resistance have primarily focused on molecular events that mediate primary or secondary resistance in patients. Less is known about the initial molecular response and adaptation that may occur in tumor cells early upon exposure to a targeted agent. Although understudied, emerging evidence indicates that the early adaptive changes by which tumor cells respond to the stress of a targeted therapy may be crucial for tumo r cell survival during treatment and the development of resistance. Here we review recent data illuminating the molecular architecture underlying adaptive stress signaling in tumor cells. We highlight how leveraging this knowledge could catalyze novel strategies to minimize
    [Show full text]
  • The SOLID-TIMI 52 Randomized Clinical Trial
    RM2007/00497/06 CONFIDENTIAL The GlaxoSmithKline group of companies SB-480848/033 Division: Worldwide Development Information Type: Protocol Amendment Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) (Short title: The Stabilization Of pLaques usIng Darapladib- Thrombolysis In Myocardial Infarction 52 SOLID-TIMI 52 Trial) Compound Number: SB-480848 Effective Date: 26-FEB-2014 Protocol Amendment Number: 05 Subject: atherosclerosis, Lp-PLA2 inhibitor, acute coronary syndrome, SB-480848, darapladib Author: The protocol was developed by the members of the Executive Steering Committee on behalf of GlaxoSmithKline (MPC Late Stage Clinical US) in conjunction with the Sponsor. The following individuals provided substantial input during protocol development: Non-sponsor: Braunwald, Eugene (TIMI Study Group, USA); Cannon, Christopher P (TIMI Study Group, USA); McCabe, Carolyn H (TIMI Study Group, USA); O’Donoghue, Michelle L (TIMI Study Group, USA); White, Harvey D (Green Lane Cardiovascular Service, New Zealand); Wiviott, Stephen (TIMI Study Group, USA) Sponsor: Johnson, Joel L (MPC Late Stage Clinical US); Watson, David F (MPC Late Stage Clinical US); Krug-Gourley, Susan L (MPC Late Stage Clinical US); Lukas, Mary Ann (MPC Late Stage Clinical US); Smith, Peter M (MPC Late Stage Clinical US); Tarka, Elizabeth A (MPC Late Stage Clinical US); Cicconetti, Gregory (Clinical Statistics (US)); Shannon, Jennifer B (Clinical Statistics (US)); Magee, Mindy H (CPMS US) Copyright 2014 the GlaxoSmithKline group of companies. All rights reserved. Unauthorised copying or use of this information is prohibited. 1 Downloaded From: https://jamanetwork.com/ on 09/24/2021 RM2007/00497/06 CONFIDENTIAL The GlaxoSmithKline group of companies SB-480848/033 Revision Chronology: RM2007/00497/01 2009-OCT-08 Original RM2007/00497/02 2010-NOV-30 Amendment 01: The primary intent is to revise certain inclusion and exclusion criteria.
    [Show full text]
  • Effect of Darapladib on Plasma Lipoprotein-Associated
    Advance Publication by-J-STAGE Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity in Japanese Dyslipidemic Patients, With Exploratory Analysis of a PLA2G7 Gene Polymorphism of Val279Phe Hiroyuki Daida, MD, PhD; Takayuki Iwase, PhD; Shigeru Yagi, BSc; Hidekazu Ando, BSc; Hiromu Nakajima, MD, PhD Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is being evaluated as a therapeutic target for treatment of atherosclerosis. This is the first study to examine the effects of darapladib, a novel selective Lp-PLA2 inhibitor, on Lp-PLA2 activity in Japanese dyslipidemic patients with/without the Val279Phe (V279F) single-nucleotide polymorphism (SNP) of the PLA2G7 gene. Exploratory analysis to examine the effects of V279F on Lp-PLA2 inhibi- tion of darapladib was also performed. Methods and Results: This was a 4-week, multicenter, randomized, double-blind, placebo-controlled, parallel- group, dose-ranging trial of darapladib in 107 Japanese patients with dyslipidemia receiving statins. Patients were randomized to placebo (n=25), darapladib 40 mg (n=28), 80 mg (n=28), or 160 mg (n=26). All darapladib doses produced sustained dose-dependent inhibition of Lp-PLA2 activity of approximately 49%, 58%, and 67%, respec- tively (P<0.001 for all comparisons). The inhibitory effect achieved a plateau by 1 week. Patients with the V279F homogenous mutation who have no circulating levels of Lp-PLA2, were excluded from the study. The Lp-PLA2 activ- ity was inhibited in both homozygous wild-type and heterozygote genotypes of the V279F polymorphism subjects to a similar extent, although the heterogeneous mutation has almost half the level of Lp-PLA2 activity compared with that of wild-type in Japanese people.
    [Show full text]
  • Overview and Perspective on RTK Heterointeractions Michael D
    Review Cite This: Chem. Rev. 2019, 119, 5881−5921 pubs.acs.org/CR The RTK Interactome: Overview and Perspective on RTK Heterointeractions Michael D. Paul and Kalina Hristova* Department of Materials Science and Engineering, Institute for NanoBioTechnology, and Program in Molecular Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States ABSTRACT: Receptor tyrosine kinases (RTKs) play important roles in cell growth, motility, differentiation, and survival. These single-pass membrane proteins are grouped into subfamilies based on the similarity of their extracellular domains. They are generally thought to be activated by ligand binding, which promotes homodimerization and then autophosphorylation in trans. However, RTK interactions are more complicated, as RTKs can interact in the absence of ligand and heterodimerize within and across subfamilies. 19 Here, we review the known cross-subfamily RTK heterointeractions and their possible biological implications, as well as the methodologies which have been used to study them. Moreover, we demonstrate how thermodynamic models can be used to study RTKs and to explain many of the complicated biological effects which have been described in the literature. Finally, we discuss the concept of the RTK interactome: a putative, extensive network of interactions between the RTKs. This RTK interactome can produce unique signaling outputs; can amplify, inhibit, and modify signaling; and can allow for signaling backups. The existence of the RTK interactome could provide an explanation for the irreproducibility of experimental data from different studies and for the failure of some RTK inhibitors to produce the desired therapeutic effects. We argue that a deeper knowledge of RTK interactome thermodynamics can lead to a better understanding of fundamental RTK signaling processes in health and disease.
    [Show full text]
  • A Molecular Dynamics Simulation Study for Variant Drug Responses Due to FMS-Like Tyrosine Kinase 3 Cite This: RSC Adv.,2017,7, 29871 G697R Mutation†
    RSC Advances View Article Online PAPER View Journal | View Issue A molecular dynamics simulation study for variant drug responses due to FMS-like tyrosine kinase 3 Cite this: RSC Adv.,2017,7, 29871 G697R mutation† Chien-Cheng Lee,a Yu-Chung Chuang,b Yu-Lin Liub and Chia-Ning Yang *b FMS-like tyrosine kinase 3 (FLT3) is an attractive target for acute myeloid leukemia. Recent studies have suggested that the application of small-molecule kinase inhibitors is a promising treatment strategy for patients with primary activating mutations of FLT3; however, the development of secondary mutations, including those of A627T, N676D, F691I, and G697R, that confer acquired resistance to kinase inhibitors has become a severe problem. In this study, we conducted a series of molecular dynamics simulations on PKC412- and sorafenib-bound FLT3 kinases and different apo forms of the FLT3 kinase to explain the minor and severe G697R mutation-induced resistance to sorafenib and PKC412, respectively. Structural analysis on our simulation results revealed that the type II kinase inhibitor sorafenib (IC50 ¼ 9 nM) Creative Commons Attribution 3.0 Unported Licence. assesses its binding site through either the adenine pocket entrance or the back pocket entrance, whereas the type I kinase inhibitor PKC412 (IC50 ¼ 35 nM) intercalates to its binding site from the front pocket entrance. The G697 residue is located at the end of the FLT3 kinase hinge segment and is close to the front and adenine pockets. In G697R mutation where the substituted R697 residue affects both the front and adenine pocket entrances in different manners, sorafenib may approach its binding site Received 11th April 2017 through the back pocket entrance, whereas PKC412 is blocked by the FLT3 kinase.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Radotinib Item No. 19923 CAS Registry No.: 926037-48-1 Formal Name: 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5- (trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2- N pyrimidinyl]amino]-benzamide H N Synonym: IY-5511 N N MF: C H F N O N N N 27 21 3 8 O FW: 530.5 H N Purity: ≥98% UV/Vis.: λmax: 215, 270 nm CF3 Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Radotinib is supplied as a crystalline solid. A stock solution may be made by dissolving the radotinib in the solvent of choice. Radotinib is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of radotinib in these solvents is approximately 10 and 3 mg/ml, respectively. Description Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl, with an IC50 value of 30.6 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form.1 Radotinib also inhibits platelet-derived growth factor receptors (PDGFRs) α 2,3 and β with IC50 values of 75.5 and 130 nM, respectively. Binding of radotinib to Bcr-Abl in vitro inhibits the phosphorylation of the downstream signaling mediator CrkL.3 In acute myeloid leukemia cells, in vitro treatment with radotinib at doses of 10-100 µM reduces viability, activates the mitochondrial apoptosis pathway, and promotes expression of the differentiation marker CD11b.2 References 1.
    [Show full text]
  • FLT3 Inhibitors in Acute Myeloid Leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2*
    Wu et al. Journal of Hematology & Oncology (2018) 11:133 https://doi.org/10.1186/s13045-018-0675-4 REVIEW Open Access FLT3 inhibitors in acute myeloid leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2* Abstract FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents. Keywords: FMS-like tyrosine kinase 3 inhibitors, Acute myeloid leukemia, Midostaurin, FLT3 Introduction RAS, MEK, and PI3K/AKT pathways [10], and ultim- Acute myeloid leukemia (AML) remains a highly resist- ately causes suppression of apoptosis and differentiation ant disease to conventional chemotherapy, with a me- of leukemic cells, including dysregulation of leukemic dian survival of only 4 months for relapsed and/or cell proliferation [11]. refractory disease [1]. Molecular profiling by PCR and Multiple FLT3 inhibitors are in clinical trials for treat- next-generation sequencing has revealed a variety of re- ing patients with FLT3/ITD-mutated AML. In this re- current gene mutations [2–4]. New agents are rapidly view, we summarized the preclinical and clinical studies emerging as targeted therapy for high-risk AML [5, 6]. on new FLT3 inhibitors, including sorafenib, lestaurtinib, In 1996, FMS-like tyrosine kinase 3/internal tandem du- sunitinib, tandutinib, quizartinib, midostaurin, gilteriti- plication (FLT3/ITD) was first recognized as a frequently nib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG mutated gene in AML [7].
    [Show full text]